On May 8, 2020, the CoVIg-19 Plasma Alliance was announced, an unprecedented partnership of the world’s leading plasma companies, spanning plasma collection, development, production, and distribution.Founding members include Biotest, BPL, CSL Behring, LFB, Octapharma, and Takeda. The Bill & Melinda Gates Foundation is providing advisory support. Microsoft is providing technology including the Alliance website and the Plasma Bot for donor recruitment.

In addition to those announced at its inception – Biotest, BPL, CSL Behring, LFB, Octapharma and Takeda – the Alliance welcomes new industry members ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. Together, these organizations will contribute specialist advisory expertise, technical guidance and/or in-kind support to contribute to the Alliance goal of accelerating development and distribution of a potential treatment option for COVID-19.

In parallel, the Alliance has confirmed it will work with the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH to test the safety, tolerability and efficacy of the hyperimmune therapy in adult patients with COVID-19. This global study is currently anticipated to start in the summer and will form the foundation for the potential regulatory approval of the hyperimmune therapy.